Lupin launches Rufinamide Tablets USP in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai Inc.

Rufinamide Tablets (RLD Banzel®) had estimated annual sales of USD 138 million in the U.S. (IQVIA MAT October 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 775.35 as compared to the previous close of Rs. 770.50. The total number of shares traded during the day was 50983 in over 2513 trades.

The stock hit an intraday high of Rs. 778.90 and intraday low of 762.35. The net turnover during the day was Rs. 39236157.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 RufinamideTablets Eisai